The Avoca Quality Consortium announced its key initiatives for 2014.
The Avoca Quality Consortium announced its key initiatives for 2014, with a significant move to a change in its membership. That is it will offer Associate Consortium
Membership to companies that provide products and services in support of clinical development. This addresses what the Consortium believes will foster increased industry collaboration.
Other initiatives include:
The Consoritum was founded in 2012 as an opportunity to bring sponsors and CROs together to accelerate the development of best practices and industry standards for proactive quality management. The Avoca Quality Consortium is led by The Avoca Group, Inc., a Princeton-based consulting firm.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.